[REVISION HISTORY]

Eli Lilly Q2 2026 earnings and revenue surge

Updated 5 times since CLSTR started tracking revisions of this situation.

What changed

2026-08-06 13:48 UTC → 2026-08-06 17:02 UTC · added ~~removed~~

Eli Lilly’s shares rose modestly on July 28, 2026 after analysts lifted price targets ahead of its earnings release. The company ~~then~~ posted Q2 2026 non‑GAAP earnings of $8.38 per share, ~~far exceeding~~ well above the $6.07 consensus, and revenue of about $23 billion – a 48 % year‑over‑year increase driven by its obesity‑treatment portfolio. Sales of the diabetes drug Mounjaro ~~generated~~ jumped 91 % to $9.9 billion ~~in sales (up 91 %)~~ and the weight‑loss drug Zepbound ~~contributed $4.9 billion (up~~ grew 44 ~~%). The firm noted that worldwide~~ % to $4.9 billion, together accounting for roughly two‑thirds of quarterly revenue. Worldwide realized prices for ~~its weight‑loss drugs~~ the GLP‑1 medicines fell 13 % (3 % in the United States, 36 % ~~outside the U.S.)~~ outside) after Mounjaro entered China’s national reimbursement list. Adjusted net income rose 32 % to $7.5 billion, prompting Lilly to raise its full‑year 2026 revenue outlook to $85‑$87 billion and reaffirm its EPS target. In the same quarter Lilly launched an oral obesity pill, Foundayo, which generated $98 million in sales, short of the $105.6 million analysts had expected.

Versions

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.